

Item: 6.3

Report to:	NHS Hull CCG Board
Date of Meeting:	28 January 2022
Title of Report:	GP Practice / PCN involvement in COVID19 Research and Development projects/programmes, April 2020 to December 2021
Presented by:	Phil Davis, Strategic Lead – Primary Care
Author:	Marie Girdham, R and D Lead Nurse Manager, Humber CCGs

STATUS OF THE REPORT:

To approve	<input type="checkbox"/>	To endorse	<input type="checkbox"/>
To ratify	<input type="checkbox"/>	To discuss	<input type="checkbox"/>
To consider	<input type="checkbox"/>	For information	<input type="checkbox"/>
To note	<input checked="" type="checkbox"/>		

PURPOSE OF REPORT:

The purpose of this paper is to provide an executive summary to Hull CCG Board on Primary Care Network (PCN) and GP Practice involvement in COVID19 Research throughout 2020 and 2021 along with information of ongoing developmental programmes and projects.

RECOMMENDATIONS:

It is recommended that the CCG Board note the information provided in the report.

REPORT EXEMPT FROM PUBLIC DISCLOSURE No Yes

If yes, detail grounds for exemption

CCG STRATEGIC OBJECTIVE *(See guidance notes on page 4)*

4, 5, 6, 8 and 9

Short summary as to how the report links to the CCG's strategic objectives

The report recognised the role of R & D in the pandemic and provides the evidence that NHS Hull Clinical Commissioning Group, including through member practices and Primary Care Networks, still continues to maintain and develop its statutory duty to 'promote research, innovation and the use of research evidence' (Health and Social Care Act, 2012).

IMPLICATIONS: *(summary of key implications, including risks, associated with the paper),*

Finance	No impact identified financially for Hull CCG
HR	No risks identified
Quality	Support for involving the patients in research studies is one of the indicators for quality health care and a mandatory part of the quality reports accounts.
Safety	<p>The legislative frameworks that support R & D link into the Health Research Authority (HRA) and set out the safety requirements and assurances needed to minimise any risk to patient safety.</p> <p>The HRA have put additional measures in place to essentially review Urgent Public Health COVID 19 studies, the information has been updated on the HRA web site.</p>

ENGAGEMENT: *(Explain what engagement has taken place e.g. Partners, patients and the public prior to presenting the paper and the outcome of this)*

N/A.

LEGAL ISSUES: *(Summarise key legal issues / legislation relevant to the report)*

As recognised in the Health and Social Care Act (2012) the CCG is mandated to promote research and the use of research evidence.

EQUALITY AND DIVERSITY ISSUES: (summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). **All** reports relating to new services, changes to existing services or CCG strategies / policies **must** have a valid EIA and will not be received by the Committee if this is not appended to the report)

	Tick relevant box
An Equality Impact Analysis/Assessment is not required for this report.	√
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

THE NHS CONSTITUTION: (How the report supports the NHS Constitution)

The NHS Constitution confirms the commitment of the NHS 'to the promotion and conduct of research.' NHS Hull CCG is fully compliant with this provision of the NHS Constitution.